Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3
Conditions
Interventions
PeptiCRAd-1
Cyclophosphamide
+1 more
Locations
3
Germany
Krankenhaus Nordwest
Frankfurt, Germany
National Center for Tumor Diseases
Heidelberg, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Start Date
February 2, 2023
Primary Completion Date
October 30, 2026
Completion Date
December 31, 2026
Last Updated
September 5, 2025
NCT06043817
NCT06393374
NCT06257264
NCT07144280
NCT06758401
NCT07525869
Lead Sponsor
Valo Therapeutics Oy
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions